Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer.

Eberhardt NL, Grebe SK, McIver B, Reddi HV.

Mol Cell Endocrinol. 2010 May 28;321(1):50-6. doi: 10.1016/j.mce.2009.10.013. Review.

2.

Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation.

Giordano TJ, Au AY, Kuick R, Thomas DG, Rhodes DR, Wilhelm KG Jr, Vinco M, Misek DE, Sanders D, Zhu Z, Ciampi R, Hanash S, Chinnaiyan A, Clifton-Bligh RJ, Robinson BG, Nikiforov YE, Koenig RJ.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1983-93.

3.

PAX8/PPARγ rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular the encapsulated follicular variant of papillary carcinoma.

Armstrong MJ, Yang H, Yip L, Ohori NP, McCoy KL, Stang MT, Hodak SP, Nikiforova MN, Carty SE, Nikiforov YE.

Thyroid. 2014 Sep;24(9):1369-74. doi: 10.1089/thy.2014.0067.

4.

The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis.

Reddi HV, McIver B, Grebe SK, Eberhardt NL.

Endocrinology. 2007 Mar;148(3):932-5. Review.

PMID:
16946003
5.

Is thyroid follicular cancer in Japanese caused by a specific t(2; 3)(q13; p25) translocation generating Pax8-PPAR gamma fusion mRNA?

Hibi Y, Nagaya T, Kambe F, Imai T, Funahashi H, Nakao A, Seo H.

Endocr J. 2004 Jun;51(3):361-6.

6.

The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma.

McIver B, Grebe SK, Eberhardt NL.

Curr Drug Targets Immune Endocr Metabol Disord. 2004 Sep;4(3):221-34. Review.

PMID:
15379724
7.

Paired box gene 8-peroxisome proliferator-activated receptor-gamma fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice.

Diallo-Krou E, Yu J, Colby LA, Inoki K, Wilkinson JE, Thomas DG, Giordano TJ, Koenig RJ.

Endocrinology. 2009 Nov;150(11):5181-90. doi: 10.1210/en.2009-0701.

8.

[Pathogenesis of differentiated thyroid cancer (papillary and follicular)].

Maciel RM, Kimura ET, Cerutti JM.

Arq Bras Endocrinol Metabol. 2005 Oct;49(5):691-700. Review. Portuguese.

9.

Diagnostic and prognostic implications of the PAX8-PPARγ translocation in thyroid carcinomas-a TMA-based study of 226 cases.

Boos LA, Dettmer M, Schmitt A, Rudolph T, Steinert H, Moch H, Sobrinho-Simões M, Komminoth P, Perren A.

Histopathology. 2013 Aug;63(2):234-41. doi: 10.1111/his.12150.

PMID:
23738683
10.

Low frequency of PAX8-PPARγ rearrangement in follicular thyroid carcinomas in Japanese patients.

Mochizuki K, Kondo T, Oishi N, Tahara I, Inoue T, Kasai K, Nakazawa T, Okamoto T, Shibata N, Katoh R.

Pathol Int. 2015 May;65(5):250-3. doi: 10.1111/pin.12270.

PMID:
25708358
11.

Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma.

Dobson ME, Diallo-Krou E, Grachtchouk V, Yu J, Colby LA, Wilkinson JE, Giordano TJ, Koenig RJ.

Endocrinology. 2011 Nov;152(11):4455-65. doi: 10.1210/en.2011-1178.

12.

Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARgamma) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor.

Lado-Abeal J, Celestino R, Bravo SB, Garcia-Rendueles ME, de la Calzada J, Castro I, Castro P, Espadinha C, Palos F, Soares P, Alvarez CV, Sobrinho-Simões M, Cameselle-Teijeiro J.

Endocr Relat Cancer. 2010 Jun 3;17(3):599-610. doi: 10.1677/ERC-09-0069.

13.

A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARgamma translocation.

Castro P, Roque L, Magalhães J, Sobrinho-Simões M.

Int J Surg Pathol. 2005 Jul;13(3):235-8.

PMID:
16086077
14.

Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations.

Lacroix L, Lazar V, Michiels S, Ripoche H, Dessen P, Talbot M, Caillou B, Levillain JP, Schlumberger M, Bidart JM.

Am J Pathol. 2005 Jul;167(1):223-31.

15.

Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas.

Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, Leite V.

J Clin Endocrinol Metab. 2002 Aug;87(8):3947-52.

PMID:
12161538
16.

Detection of PAX8-PPARG fusion transcripts in archival thyroid carcinoma samples by conventional RT-PCR.

Klemke M, Drieschner N, Belge G, Burchardt K, Junker K, Bullerdiek J.

Genes Chromosomes Cancer. 2012 Apr;51(4):402-8. doi: 10.1002/gcc.21925.

PMID:
22179975
17.

PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues.

Lacroix L, Mian C, Barrier T, Talbot M, Caillou B, Schlumberger M, Bidart JM.

Eur J Endocrinol. 2004 Sep;151(3):367-74.

18.

Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.

Banito A, Pinto AE, Espadinha C, Marques AR, Leite V.

Clin Endocrinol (Oxf). 2007 Nov;67(5):706-11.

PMID:
17651453
19.

Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas.

Cheung L, Messina M, Gill A, Clarkson A, Learoyd D, Delbridge L, Wentworth J, Philips J, Clifton-Bligh R, Robinson BG.

J Clin Endocrinol Metab. 2003 Jan;88(1):354-7.

PMID:
12519876
20.

PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected].

Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA.

Science. 2000 Aug 25;289(5483):1357-60. Erratum in: Science 2000 Sep 1;289(5484):1474.

Supplemental Content

Support Center